Action KRRO KORRO BIO, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Korro Bio, Inc.

Actions

KRRO

US5009461089

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 24/04/2024 		Varia. 5j. Varia. 1 janv.
62,99 USD -7,29 % Graphique intraday de Korro Bio, Inc. -9,11 % +31,42 %
24/04 Un initié de Korro Bio a acheté des actions d'une valeur de 999 992 $, selon un récent dépôt auprès de la SEC MT
24/04 Un initié de Korro Bio a acheté des actions d'une valeur de 999 992 $, selon un récent dépôt auprès de la SEC MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio, Inc. announced that it has received $69.959848 million in funding from Atlas Venture L.P., Deep Track Capital, LP, Blue Owl Healthcare Opportunities, Rock Springs Capital Management LP, Tri Locum Partners LP, New Enterprise Associates, Inc.
Korro Announces $70 Million Private Placement
Korro Bio, Inc. announced that it expects to receive $69.959848 million in funding from Atlas Venture L.P.
Korro to Participate in Upcoming Investor Conferences
Korro Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
North American Morning Briefing : Stocks Struggle After New Records
North American Morning Briefing : Inflation -2-
Korro Bio: Development and Application of Graph Neural Networks to Design Guide Oligonucleotides that Promote RNA Editing
Korro to Present at the TD Cowen 44th Annual Health Care Conference
Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio
Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Korro Announces Selection of Its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action KRRO
  4. Actualités Korro Bio, Inc.
  5. Autres langues